• tyc7111cc太阳成集团

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2100043429】Which score to predict diabetes remission?

    基本信息
    登记号

    ChiCTR2100043429

    试验状态

    结束

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2021-02-17

    临床申请受理号

    /

    靶点

    /

    适应症

    diabetes

    试验通俗题目

    Which score to predict diabetes remission?

    试验专业题目

    Predicting diabetes remission after bariatric surgery: Which score should we use?

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    To validate the performance of available risk prediction scores for diabetes remission 1 year after surgical treatment and determine optimal model.

    试验分类
    试验类型

    连续入组

    试验分期

    回顾性研究

    随机化

    As the design of the study is retrospective and comprises only one group, the randomization procedure was not required.

    盲法

    N/A

    试验项目经费来源

    The study required no funding

    试验范围

    /

    目标入组人数

    252

    实际入组人数

    /

    第一例入组时间

    2019-10-22

    试验终止时间

    2020-06-10

    是否属于一致性

    /

    入选标准

    We included consecutive patients with T2DM who underwent bariatric surgery, eighter laparoscopic sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) in our hospital and completed 1 year of postoperative follow-up.；

    排除标准

    Patients with already existing severe complications of T2DM, type 1 diabetes mellitus as well as history of bariatric surgery and those who were qualified for reoperation were excluded from the study.；

    研究者信息
    研究负责人姓名
    试验机构

    The study required no funding

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    The study required no funding的其他临床试验

    更多

    波兰2nd Department of General Surgery, Jagiellonian University Medical College, Kraków, Poland.的其他临床试验

    更多

    最新临床资讯

    tyc7111cc太阳成集团企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品

    同适应症药物临床试验

    更多